New Brunswick Health Research Foundation

Fondation de la recherche en santé du Nouveau-Brunswick

UNIVERSITÉ DE MONCTON
CAMPUS DE MONCTON

6th Annual New Brunswick Health Research Conference

from discovery to impact:
creating BIG changes

PRESENTED BY THE
NEW BRUNSWICK HEALTH RESEARCH FOUNDATION
WITH THE UNIVERSITÉ DE MONCTON

NOVEMBER 13 & 14, 2014

DELTA BEAUSÉJOUR | MONCTON | NEW BRUNSWICK

New Brunswick Health Research Foundation | Fondation de la recherche en santé du Nouveau-Brunswick

UNIVERSITÉ DE MONCTON
EDMUNDSTON MONCTON SHIPPAGAN

CONFERENCE SPONSORS

Université de Moncton and NBHRF wish to acknowledge the support, through educational grants and/or sponsorships, of the following organizations, whose contributions helped make this event possible.

PLATINUM

R&D

MERCK
Be well

SANOFI

SILVER

janssen
PHARMACEUTICAL COMPANIES
OF Johnson&Johnson

Boehringer Ingelheim

BRONZE

Pfizer

Lilly
Answers That Matter.

FRIENDS OF THE CONFERENCE

SERVIER

MEDAVIE BLUE CROSS™

Premier's Message

You are innovators and your ideas provide a foundation for a better, smarter healthcare system in New Brunswick.

Job creation is the main priority of our government, and innovation is essential as we work to stimulate economic development in our province. We believe in the tremendous economic potential of our people and our province.

We need to establish innovative social programs to make New Brunswick the best place to raise a family and make life more affordable.

Our government's commitment to residents is also to provide quality healthcare services. We will need to be bold and innovative in the coming years to address our shared challenges and achieve better health outcomes.

As Premier, I took on the role of Minister responsible for Innovation for a simple reason: we must find new and better ways of delivering public services to our fellow residents, while fostering job creation. Nowhere is this more pressing than our healthcare system where we have the opportunity to raise the standard of living and quality of life of friends and neighbours across our province, all the while finding important savings.

Our health researchers give us the understanding and tools to reach this goal. Whether it is research on mental health, aging and dementia, cancer, chronic diseases or the means by which we offer our public services through better primary health care approaches, each new discovery contributes to this greater good. The amazing researchers and ideas that we honour this weekend speak to the power of health research to transform lives.

I want to thank the New Brunswick Health Research Foundation and its partners for their leadership. The success in attracting new partnerships and investments in our province are noteworthy, along with the new networks that have been built across different fields of research. These allow us to accelerate our discovery process and bring tangible solutions to citizens.

The 6th Annual New Brunswick Health Research Conference brings together some of the best minds in our province to reflect on these opportunities and celebrate our growing capacity for health research and innovation.

I am pleased to welcome you to the Greater Moncton area for this gathering. I know that my colleague, Health Minister Victor Boudreau, joins me in wishing you a great conference. We thank you for your passion and contribution to the healthcare system.

Honourable Brian Gallant
Premier



New Nouveau Brunswick

Welcome Comments

Dr. Rodney Ouellette

Chair, NBHRF

Dear Conference Attendees:

As Chair and on behalf of the Board of Directors of the New Brunswick Health Research Foundation, it is my privilege and pleasure to welcome you to Moncton for our 2014 Annual Conference. A goal of the Annual Conference is to showcase the excellent health research that is happening around the province. Every year, the event grows in scope and increasingly serves as a catalyst for health research discussions and collaborations.

With each passing year, it is obvious that health research in New Brunswick is gaining momentum and, together, we are having positive health and socio-economic impacts with our discoveries and the training of future researchers. This upward trend should serve as a motivation factor as we continue to grow together this important R&D sector.

The program of this year's Conference features leading edge topics and recognized authorities in their fields. It is a great forum for students and trainees to interact with other health researchers and to cross pollinate ideas and create new research directions. It is our wish that this event be a catalyst for collaborations for the success of health research in New Brunswick since we are stronger together.

It is an exciting time for health research in New Brunswick with increasing opportunities for research and a growing critical mass of researchers and expertise. We can anticipate a continued focus on the R&D and innovation agenda from the province of New Brunswick under the leadership of the new Premier, Mr Brian Gallant. I am certain that NBHRF will be a key element in order to foster growth with funding for projects, teams and personnel. Our Board of Directors and Leadership Team know that our talented researchers will rise to the challenge and continue to conduct world class research which will impact human health and benefit our province.

I would like to thank the team of NBHRF under the leadership of CEO, Dr. Bruno Battistini who again worked tirelessly to organize this event. A special thank you to the Advisory Committee, Chair Stephen Lewis, Sandra Turcotte, Michel Johnson, Ann Beaton, Kevin Englehart and Ansar Hassan, who did a tremendous job to develop the scientific program for this year's meeting. It is our wish that you will find collaborators and innovative ideas with other attendees at the conference. The Foundation hopes that the links created here will grow stronger and researchers will provide feedback and advice to grow the event for future years. We encourage all participants to visit the NBHRF website and stay connected via Twitter to get the latest updates on announcements and programs as well as building a connected researcher network.

Thank you for participating and helping to build the future of New Brunswick Health Research.

Enjoy the conference!

Welcome Comments



Dr. Bruno Battistini

CEO, NBHRF

Dear Colleagues and Stakeholders of the Health Research Enterprise:

Welcome to Moncton. As this is my third annual health research conference since becoming a New Brunswicker, I have now completed my first tour of our three health research Hubs – lets call them our ***"New Brunswick BioMed Cities"***. (I have a plan that I'll share soon enough).

In the meantime, we are making our way through the 2nd fiscal year (2014-15) of our five-year strategic investment plan, and what changes there have been. With our annual conference it is tradition to give the yearly ***State of the Foundation Address*** including the previous year's annual report and the forecast of where we are heading.

This annual conference constitutes a unique opportunity to meet, exchange ideas and build new synergies, especially in the era of SPORs. If you don't know about SPORs, you have been hiding in a cave! We made choices, we aligned our efforts, and while we still have to bridge gaps, *our discoveries are starting to impact the system*, that is, our research is impacting the health care delivery system.

Conference *Numero VI* has the classical features of concurrent workshops, such as presentations from our own researchers, and, new this year, those from the next generation that we are financially and scientifically mentoring and "recognizing"; all SPOR updates; state-of-the-art keynote addresses from national experts and the returning and much anticipated Gairdner Lecture. A special mention also to our 2nd Gala of Excellence to name and celebrate the Senior Health Research of the year – *Spotlight on Mentors who Dare to Dream*. While you read this note, we have already embarked into year 3 of this program, 2014-15, leading to identifying the 2015 Clinician Health Researcher of the year at the next conference to be held in Fredericton.

Thank you to our Chair and dedicated Board Members – always supportive. Welcome to the new Premier, Brian Gallant, New Brunswick headmaster for innovation, and his Ministerial team. Thank you to the Local Organizing Committee lead by Dr. Stephen Lewis from ACRI/UdeM, and a special mention to our Sponsors (many returning) from the bio-pharma industry who are also engaged in several strategic initiatives, here at home in New Brunswick.

DAY 1 – THURSDAY, NOVEMBER 13, 2014

0730 - 0845
Mezzanine

REGISTRATION – COFFEE AND TEA

0845 - 0900
Ballroom A/B

OPENING REMARKS

Dr. Rodney Ouellette, Chair, NBHRF Board of Directors
Dr. Bruno Battistini, CEO, NBHRF
Dr. Stephen Lewis, President of the 2014 Local Organizing Committee, Asst-Director. Atlantic Cancer Research Institute (ACRI), Adjunct-Professor, Université de Moncton
Dr. André Samson, Vice-President Academic and Research, Université de Moncton

0900 - 0930
Ballroom A/B

PLENARY SESSION #1 – STATE OF THE FOUNDATION ADDRESS

Dr. Bruno Battistini
Chief Executive Officer,
NBHRF

New Brunswick Health Research Foundation
Fondation de la recherche en santé du Nouveau-Brunswick

Abstract

The NBHRF CEO will present and release the previous fiscal year's Annual Impact Report, profiling the activities and vitality of the health research enterprise in New Brunswick. The address will also showcase ongoing and future programming proposed in its five year strategic investment plan (2013-2018) that are planned to energize health research and innovation in our province, contributing to a significant growth of the knowledge economy.

0930 - 1015
Ballroom A/B

PLENARY SESSION #2 – KEYNOTE ADDRESS #1

Introduced by: Dr. Bruno Battistini, Chief Executive Officer, NBHRF

Keynote Speaker:



Drug Design for Alzheimer's Disease Leading to Micropharma

Dr. Donald F. Weaver
MD, PhD, FRCPC, Director and Senior Scientist,
Toronto Western Research Institute

RESEARCH at University Health Network

Biography

Donald Weaver obtained his MD (1981) from Queen's University followed by a residency in clinical neurology at Dalhousie University. He also holds a PhD in medicinal chemistry. Dr. Weaver was on faculty at Queen's University (1988-2001), and Dalhousie University (2001-2013) before being recruited to Toronto to become Director of the Toronto Western Research Institute in 2013. His research is focussed on computer-aided drug design of novel therapeutics for chronic neurological disorder, particularly dementia and epilepsy. He has more than 160 publications and holds more than 70 patents. He has co-founded eight start-up biotech companies and has co-designed two agents that have reached Phase III human clinical trials. His most recent company, Treventis Corp., recently received $4.7M from the Wellcome-Trust to develop innovative therapies for Alzheimer's dementia. His work has been recognized with multiple national and international awards including the S. Weir Mitchell Award from the American Academy of Neurology and the Prix Galien Canada 2009 Research Award for his pharmaceutical research.

Abstract

Alzheimer's disease (AD) is the most common form of dementia, affecting more than 40% of people by age 90 years. AD arises from the misfolding of two proteins implicated in the aetiology and pathogenesis of the disorder: beta-amyloid and tau. There are no disease modifying drugs available for the curative treatment of AD. Using computer aided drug design methods we have devised two in silico models for the design of therapeutics for AD. Both of these are in silico models of beta-amyloid and/or tau misfolding. Using these models, we have screened an in silico library of more than 11.8 million compounds, identifying three new classes of new chemical entities capable of preventing protein misfolding. More than 1,000 analogues of these compounds have been designed, synthesized, characterized, purified, and assessed in a battery of in vitro assays. Selected agents have been progressed to in vivo models of AD. In addition, we have created micropharma companies to continue the knowledge translation of these agents to the marketplace. This journey, complete with pitfalls, will be discussed.

DAY 1 – Thursday, November 13, 2014 – continued

1015 - 1045
Mezzanine

NUTRITION BREAK, POSTER VIEWING AND JUDGING

1045 - 1130
Ballroom A/B

PLENARY SESSION #3

Introduced by: Dr. Ansar Hassan, MD, PhD, Asst-Prof., Cardiac Surgeon, Dept Cardiac Surgery, NBHC, SJRH

Keynote Speaker:

Virus Based Therapies for Cancer Treatment

Dr. John C. Bell
Senior Scientist, Cancer Therapeutics,
Ottawa Hospital Research Institute

Biography

Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. His research program is directed towards the identification and characterization of novel viruses that specifically infect and kill cancer cells.

Abstract

Current cancer therapies using chemotherapy and radiation have toxic side effects that limit their ability to treat patients with advanced cancers. Viruses designed or selected to specifically infect and destroy tumours have few and minor side effects and hold the promise to be more effective therapeutics. Our experience in the design, testing and translation of our virus products into human testing will be discussed.

1130 - 1200
Ballroom A/B

PLENARY SESSION #4: OPEN DISCUSSION – KNOWLEDGE TRANSLATION – TECHNOLOGY TRANSFER

Chair/Moderator: Dr. Jack Stewart, Chief Science Officer, Soricimed, Mount Allison University Professor of Biochemistry Alumni

Panelists:

Dr. Donald F. Weaver, MD, PhD, FRCPC, Director and Senior Scientist, Toronto Western Research Institute
Dr. John C. Bell, Senior Scientist, Cancer Therapeutics, Ontario Hospital Research Institute
Ms. Sophie Thériault, Director, Business Development and Communications, ACRI

Biography

Ms. Thériault is responsible for the business development and communications activities of ACRI. She has extensive knowledge of the law of intellectual property, technology transfer, licensing and business development and economic development. She is also responsible for all aspects of strategic communications including media relations, promotional activities and philanthropy. Originally from New Brunswick, Ms. Thériault is a graduate of the University of Ottawa with a degree in communications and has a law degree from the University of Moncton. She has practiced technology transfer at Laurentian University and Mount Allison University.

1200 - 1245
Ballroom C

BUFFET LUNCH

1245 - 1330
Mezzanine

POSTER VIEWING AND JUDGING

DAY 1 – Thursday, November 13, 2014 – continued

1330 - 1500
Ballroom A/B

CONCURRENT SESSION – WORKSHOP #1:
HOT TOPICS IN RESEARCH ON AGING IN NEW BRUNSWICK

Chair/Moderator: Dr. Odette Gould, Professor, Department of Psychology, Mount Allison University

Speaker:

Aging-in-Place in New Brunswick

Dr. Suzanne Dupuis-Blanchard
CNFS - Université de Moncton Research Chair in Population Aging; Director, Research Centre on Aging; Associate Professor, School of Nursing

UNIVERSITÉ DE MONCTON
EDMUNDSTON MONCTON SHIPPAGAN

Biography

Suzanne Dupuis-Blanchard is the CNFS-Université de Moncton Research Chair in Population Aging, the director of the Centre for Aging Research, and an associate professor at the School of Nursing of the Université de Moncton in Moncton, New Brunswick. Her research program concerns aging in place.

Abstract

Aging-in-place initiatives in New Brunswick: The concept of aging-in-place is making grounds as a long term care option in Canada. However, for this care option to be effective, older adults need to have access to appropriate services. The goal of this presentation is to explain the realities of aging in place for seniors in New Brunswick and to discuss the importance of collaboration with community partners in the advancement of aging care.

Panelists:

Mr. Jean-Luc Bélanger
Directeur général – Association francophone des aînés du N.-B.

AFANB

Biography

Executive director of the Association francophone des aînés du Nouveau-Brunswick, co-chair of the Regroupement d'Action communautaire, member of the executive of the Société santé et mieux-être francophone du Nouveau-Brunswick, and member of the committee of the Research Chair in Population Aging of the Université de Moncton, he is completing a four-year term as a member of the board of directors of the national organization Société santé en français. In 1992, he was awarded the Order of Canada as the founding father of the Acadian Games and for his community involvement.

Ms. Jodi Hall
Director of Operations,
New Brunswick Association of Nursing Homes

The New Brunswick Association of NURSING HOMES
L'Association des FOYERS DE SOINS du Nouveau-Brunswick

Biography

Jodi Hall is the Director of Operations with the New Brunswick Association of Nursing Homes; a position she has been in for the last four years. She has a Master's degree in Health Studies with a major in Leadership from Athabasca University and a Bachelor in Adult Education from the University of New Brunswick. She also has a diploma in practical nursing. Jodi has had an interesting career in healthcare, starting when she was in high school; she held a part-time job in the dietary department at the DVA Unit in Fredericton! Since that time, Jodi has served as the Director of Education and Practice with the New Brunswick Licensed Practical Nurse Association and Administrator of Orchard View Long Term Care prior to her current position. She was a contributor to the Premier's Panel on Healthy Aging Report, and is pleased to be a part of the group that is working to establish a provincial Collaborative for Healthy Aging Care to support the aging experience in NB.

DAY 1 – Thursday, November 13, 2014 – continued

1330 - 1500
Shediac B/C

CONCURRENT SESSION – WORKSHOP #2:
SUMMER STUDENTSHIP AWARDEES PRESENTATIONS

Chair/Moderator: Ms. Mary Butler, VP College and Community Development, NBCC

Speakers:



Approach to Automated Laboratory Utilization Auditing in NB

Mr. Ronald Yan
Dalhousie Medicine New Brunswick

Mentor: Dr. Yu Chen

DALHOUSIE UNIVERSITY *Inspiring Minds*

Abstract

With a great deal of healthcare spending on laboratory testing, appropriate utilization can offer significant cost benefit to the healthcare system. Detailed analytics allow us to identify patterns of testing and apply restrictions as appropriate. This presentation will showcase a data analytics solution that is being tested at the Department of Laboratory Medicine at the Dr. Everett Chalmers Regional Hospital to audit laboratory assay utilization.

Anticancer drug leads from traditionally used Canadian medicinal plants

Ms. Allison Bos
University of New Brunswick, Saint John

Mentor: Dr. Christopher Gray

UNB Saint John

Abstract

Cancer is a leading cause of death in Canada and, due to the limited knowledge about this disease, drug-drug interactions and the increasing emergence of drug resistance, new anticancer therapeutics are needed. One strategy in identifying potential anticancer drug candidates is through investigation of the effect of plant-derived natural products on apoptotic activity in tumour cells. Preliminary screening of our library of crude extracts from 35 traditionally used Canadian medicinal plants has identified 23 extracts that exhibit potent anti-proliferative and apoptotic inducing activities against the highly malignant breast carcinoma cell line, MDA-MB-231. Populus tremuloides bark, used extensively by First Nations peoples for a variety of illnesses, yielded one of the most promising extracts. Bioassay guided fractionation of the bark extract has revealed fractions that induce apoptosis in human breast cancer cells prompting further phytochemical investigation. We are continuing to isolate natural products from the bark extract with the objective of finding novel chemical scaffolding to serve as potential anticancer drug leads.

Metabolomics and Glioblastoma Multiforme: The key to overcome the resistance?

Mr. Patrick-Denis St. Coeur
Université de Moncton

Mentor: Dr. Pier Morin

UNIVERSITÉ DE MONCTON EDMUNDSTON MONCTON SHIPPAGAN

Abstract

Glioblastoma multiforme (GBM) is the most aggressive and prevalent form of brain tumor. GBM is still impossible to cure completely due to treatment resistance. A challenge remains of determining if a patient will respond to temozolomide (TMZ), the only chemotherapeutic agent available for this cancer. Cell metabolism differs between healthy and cancerous cell types. This work leverages a metabolomics approach with the overarching objective of identifying a metabolic signature with diagnostic potential that can discriminate between TMZ-resistant and TMZ-sensitive GBM patients.

DAY 1 – Thursday, November 13, 2014 – continued

microRNA profiling and target prediction in Renal Cell Carcinoma

Ms. Sonia Dastous
Université de Moncton

Mentor: Dr. Sandra Turcotte

Abstract

Kidney cancer is the eight most common diagnosed cancer in Canada. These tumors are particularly challenging since they are resistant to most cytotoxic therapies. Thus, better understanding of renal pathogenesis is crucial. MicroRNAs (miRNA) are small noncoding RNAs that inhibit mRNA translation and have been associated with cancer. It is estimated that the von Hippel-Lindau (VHL) gene is inactivated in up to 85% of RCC. Our study aimed to identify miRNA that are VHL-dependent and their potential targets that could be involved in RCC carcinogenesis. Using next-generation sequencing, we found 93 miRNAs that were differently expressed according to the VHL gene expression. Among them, 16 have been tested and 6 were validated in three different cell lines showing the heterogeneity of RCC tumors. Bioinformatics analysis predicted several targets associated with these miRNA. Our results identified miRNAs that are VHL-regulated. The biological relevance of the miRNA candidates remain to be elucidated and may potentially serves as a target in RCC.

Experiences of the Exceptionally Old Living in New Brunswick: Friends, Agism, and Health

Ms. Maryani Lesmana
St. Thomas University

Mentor: Dr. Lynne Gouliquer

Abstract

Social functioning (e.g., social engagement, activities, and positive relationship with others) plays a pivotal role for the health of older adults (Berg et al., 2009; Gabriel & Bowling, 2004). Using the Psycho-Social Ethnography of the Commonplace (P-SEC) methodology, fifteen 90+year-old Canadians living relatively independently, took part in a study. Results highlight the challenges associated with maintaining friendships. How the exceptionally old made sense of these complications and the coping strategies they utilised are explored. The discussion examines how age segregation in Canadian society contributes to the reduced social functioning for exceptionally older adults.



The effects of novel HDAC inhibitors on viability and expression in human breast cancer cells

Mr. Ryan Pinkham
Mount Allison University

Mentor: Dr. Vett Lloyd

Abstract

Many forms of cancer are characterized by an increase in histone deacetylase (HDAC) activity. In this study, novel HDAC inhibitors were designed and tested for their efficacy at inhibiting HDAC proteins in vitro, and for their effect on breast cancer cell line mobility and viability, and the overall expression of HDACs therein.

1500 - 1630
Mezzanine

NUTRITION BREAK, POSTER VIEWING AND JUDGING

DAY 1 – Thursday, November 13, 2014 – continued

1630 - 1745
Ballroom A/B

PLENARY SESSION #5 – 2014 GAIRDNER AWARD RECIPIENT LECTURE

Moderator: Dr. John Steeves, Dean, Dalhousie Medicine New Brunswick

Introduced by: Dr. David Burns, Vice President (Research), University of New Brunswick

Speaker:

Dr. Guy A. Rouleau
Director, Montreal Neurological Institute and Hospital,
McGill University, Wilder Penfield Chair in Neuroscience
as Professor of Neurology and Neurosurgery at McGill, and
Canada Research Chair in Genetics of the Nervous System

gairdner
LES PRIX CANADA GAIRDNER AWARDS
www.gairdner.org

Biography

Dr. Rouleau comes to The Neuro from the Université de Montréal, where he was Director of the CHU Ste-Justine Research Centre and founder and Director of the Centre of Excellence in Neuroscience. There he held the Canada Research Chair in Genetics of the Nervous System as well as the Jeanne-et-J.-Louis-Levesque Chair in Genetics of Brain Diseases. Dr. Rouleau is Director of the Réseau de Médecine Génétique Appliquée – Fonds de recherche du Québec - Santé.

Dr. Rouleau obtained his MD (Magna Cum Laude) in 1980 from the University of Ottawa and his PhD in Genetics at Harvard University in 1989. His post-graduate research in neuroscience was conducted at the Montreal Neurological Institute and at Massachusetts General Hospital. Dr. Rouleau conducted his clinical training in internal medicine at the Montreal General Hospital, neurology residency at the Montreal Neurological Institute, and research fellowship at the Massachusetts General Hospital.

Dr. Rouleau's landmark achievements are his contributions to the identification of over 20 disease-causing genes and his discovery of new mutational mechanisms. Over the last 25 years, Dr. Rouleau and his team have focused on understanding the genetic basis for diseases and identifying genes causing neurological and psychiatric diseases including amyotrophic lateral sclerosis, stroke, Essential Tremor, familial aneurysms, cavernous angiomas, epilepsy, spinocerebellar ataxia, spastic paraplegia, autism, Tourette syndrome, restless legs syndrome, schizophrenia and bipolar disorder. He has published more than 500 articles in top peer-reviewed journals such as The Lancet, Cell, and Nature, as well as 40 review articles and book chapters. His work has been cited over 30,000 times. He has delivered more than 130 lectures around the world. He has supervised many students (9 Master's, 40 PhD, and 44 post-doctoral fellows). Many of his former students are now professors at universities in Brazil, France, Portugal, Japan, the USA and Canada. He has received numerous awards, most recently the 2012 Prix du Québec – Prix Wilder Penfield, the Margolese National Brain Disorders Prize from the University of British Columbia, and the Henry Friesen Prize from the Royal College of Physicians and Surgeons of Canada / The Canadian Society for Clinical Investigation. He is an Officer of the Ordre national du Québec.

Dr. Rouleau sits on the editorial boards of major scientific journals including Neurology of Disease and Annals of Human Genetics, and performs ad hoc reviews for more than 25 journals. He also serves on several international scientific boards including the IGBMC Strategic Scientific Advisory Board, Strasbourg, France and is a board member of several foundations and societies dedicated to finding cures for nervous system diseases, including the Jumelles Coudé foundation, Ataxia of Charlevoix-Saguenay Foundation, Gairdner Medical Advisory Board, the Cole Foundation and the Canadian Academy of Health Sciences. He has also served on the panel for numerous grant committees (ex. CIHR, NIH, ALSA, ENR, NNFF, FRQS). He has founded and directed several successful companies including RGS Genome Inc., Xenon Genetics Research Inc., and Emerillon Therapeutics Inc.

1830 - 1900
Mezzanine

RECEPTION

Sponsored by: Université de Moncton

Dr. André Samson
Vice-President Academic and Research,
Université de Moncton

UNIVERSITÉ DE MONCTON EDMUNDSTON MONCTON SHIPPAGAN

1900 - 2100
Ballroom A/B

AWARD GALA BANQUET

2100 - 0100
Ballroom A/B

SOCIAL GATHERINGS

Sponsored by: ACRI

INSTITUT ATLANTIQUE DE RECHERCHE SUR LE CANCER
ATLANTIC CANCER RESEARCH INSTITUTE

SENIOR HEALTH RESEARCHERS IN NEW BRUNSWICK

SENIOR HEALTH RESEARCHERS IN NEW BRUNSWICK

LET US BE YOUR MENTORS

SENIOR HEALTH RESEARCHERS IN NEW BRUNSWICK

AWARD GALA

Banquet

of the

Senior Health Researcher in New Brunswick

Spotlight on Mentors who DARE TO DREAM

November 13, 2014

Delta Beauséjour, Moncton
750 Main St, Moncton, NB, E1C 1E6

2013-2014 Candidates

Dr. Baukje Miedema
Professor / Director, Research Dalhousie University Family Medicine Teaching Unit Fredericton; Adjunct Professor Sociology, UNB



Dr. Marc Surette
Professor, Biochemistry, New Brunswick Innovation Research Chair in Biosciences, Université de Moncton

Dr. Vett Lloyd
Associate Professor, Department of Biology, Mount Allison University

Dr. Kevin Englehart
Director, Institute of Biomedical Engineering; Professor, Electrical and Computer Engineering, UNB

Dr. Deborah K. van den Hoonaard
Professor, Gerontology, Canada Research Chair in Qualitative Research and Analysis, St. Thomas University

Dr. Barbara D'Entremont
Professor of Psychology, UNB

Dr. Sarah Pakzad
Clinical Neuropsychologist; Professor, School of Psychology, Université de Moncton

Dr. Bill Morrison
Associate Professor, Educational Psychology, Co-Executive Director, Health and Education Research Group, Faculty of Education, UNB; President Elect, NB College of Psychologists

Dr. Lucia O' Sullivan
Professor, Psychology, UNB; Director of the Experimental Program in Psychology; Canada Research Chair in Adolescents' Sexual Health Behaviour

Dr. Rodney Ouellette
President and Scientific Director Atlantic Cancer Research Institute

Dr. Denise Clark
Professor, Department of Biology, UNB

Dr. Chris McGibbon
Professor, Faculty of Kinesiology and Research Chair in Rehabilitation Biomechanics, Institute of Biomedical Engineering, UNB

2014 Peer Review Committee

Dr. Pedro D'Orleans-Juste, Université de Sherbrooke | Dr. Michelle Mottola, The University of Western Ontario | Dr. Todd Duhamel, University of Manitoba | Dr. Sandra Davidge, University of Alberta | Dr. Ian Dixon, University of Manitoba | Dr. Michel Tremblay, McGill University | Dr. Denis Deblois, Université de Montréal

Welcome

The Second Gala, together with the 6th Annual Conference on Health Research in New Brunswick, becomes a tradition to celebrate our successes, the hard work of our community and the support of our stakeholders in health research and the art of innovation. Not only does health research help to build a better health care system in New Brunswick, it is changing the face of New Brunswick. It inspires lives. This evening we recognize excellence and leadership.

Co-hosts:

The Honourable Victor Boudreau
Minister of Health and Minister Responsible for the Regional Development Corporation

Dr. Stephen Lewis
2014 Conference President

Dr. Bruno Battistini
CEO, NBHRF

Dinner:

Butter Squash and Baby Shrimp, Curry Cream Drizzle

Artesian Lettuce. Sliced Strawberries, Prociutto Crackling, Roasted Pumpkin Seeds, Vanilla Honey Vinaigrette

Mushroom dusted Roasted Pork Tenderloin

Berry and Vanilla Brûlé Tart brushed with Chocolate, topped with Apple Wine Sabayon

Coffee and Tea

Jury Selection:

Dr. Pedro D'Orleans-Juste
2014 Jury President

Concluding Remarks:

Dr. Rodney Ouellette, Chair, NBHRF

New Brunswick Health Research Foundation | Fondation de la recherche en santé du Nouveau-Brunswick | Université de Moncton Edmundston Moncton Shippagan

New Brunswick Health Research Foundation | Fondation de la recherche en santé du Nouveau-Brunswick

New Brunswick Health Research Foundation | Fondation de la recherche en santé du Nouveau-Brunswick

DAY 2 – FRIDAY, NOVEMBER 14, 2014

0730 - 0830
Ballroom C

BREAKFAST

0830 - 0930
Ballroom A/B

PLENARY SESSION #6: HOT TOPICS IN CANCER RESEARCH

Chair/Moderator: Dr. Rodney Ouellette, President and Scientific Director, ACRI

Speakers:

New Roles for the HIF Family of Transcription Factors in Cancer, Tissue Regeneration and Metabolic Disease

Dr. Amato J. Giaccia
Division Director and Professor, Radiation and Cancer Biology,
Stanford School of Medicine

STANFORD SCHOOL OF MEDICINE

Biography

Dr. Giaccia is a Professor of Radiation Oncology, Associate Chair for Research & Director of the Division of Radiation & Cancer Biology in the Department of Radiation Oncology. He also is the Director of Basic Science at the Stanford Cancer Institute and heads the Radiation Biology Program in Stanford's Cancer Center, and is Director of the Cancer Biology Interdisciplinary Graduate Program. He was awarded an American Cancer Society Junior Faculty Research Award and the Michael Fry Award from the Radiation Research Society for his outstanding contributions on understanding the molecular mechanisms of resistance promoted by the tumor microenvironment. Additionally, he was the recipient of the 2013 ASTRO Gold Medal. He co-authored the sixth & seventh editions of the textbook, "Radiation Biology for the Radiologist," with Professor Eric Hall from Columbia. In addition, he is currently the "Jack, Lulu and Sam Willson Professor in Cancer Biology" in the Stanford University School of Medicine.

Abstract

Studies during the last decade have clearly demonstrated an important role for the HIF family of transcription factors in tumor angiogenesis, metabolism and metastasis. For these reasons, a great deal of effort has gone into targeting HIF or HIF target genes for cancer therapeutics. However, it is also clear that HIF modulates important homeostatic mechanisms such as erythropoiesis, tissue regeneration and cytoprotection. Therefore, in contrast to normal tissues, the goal is to enhance HIF activity selectively in specific tissues. One approach to the selective induction of HIFs has been through the prolyl hydroxylase inhibitors. HIF is targeted for degradation in the proteasome by hydroxylation and inhibition of prolyl hydroxylation prevents binding of the VHL E3 ubiquitin ligase and HIF degradation. In this talk, I will highlight some of the exciting new discoveries regarding HIF biology in cancer and normal tissue homeostasis.

Synthetic lethality in cancer to discover new therapeutic targets

Dr. Sandra Turcotte
Research Chair – Canadian Cancer Society NB; Assistant Professor,
Department of Chemistry and Biochemistry, Université de Moncton,
Research Scientist, ACRI

UNIVERSITÉ DE MONCTON EDMUNDSTON MONCTON SHIPPAGAN

Biography

Sandra Turcotte is a New Investigator at the Atlantic Cancer Research Institute and Assistant Professor at the Université de Moncton. She completed her PhD in Biochemistry at the Université du Québec à Montréal and Post-doctoral Fellowships at Stanford University in California and at the CRCHUM in Montreal. Her research focus on developing new targeted therapy for kidney cancer based on synthetic lethality. Dr. Turcotte is a Canadian Cancer Society Research Chair in New Brunswick and a KRESCENT New Investigator awardee (2012-2015).

Abstract

About 191 300 people will be diagnosed with cancer in Canada this year. Kidney cancer is the eight most commonly diagnosed. Its incidence has increased over the last 20 years, contributing to an increase in mortality rate. There is no effective therapy for patient with metastatic Renal Cell Carcinoma (RCC) since these tumors are resistant to cytotoxic therapies. One promising approach to kill tumor cells and spare normal tissue is based on the concept of synthetic lethality, which target genes that are only altered in cancer cells. Mutations that inactivate the von Hippel-Lindau (VHL) gene are common and early in RCC carcinogenesis. By identifying a small molecule, STF-62247 we demonstrated that targeting the loss of VHL could lead to a promising therapeutic strategy. Recently, we used different omics platforms to investigate the mechanism of action of this small molecule and identify potential targets. Furthermore, we used RNAi screen to exploit cancer-specific gene mutations that could make kidney cancer cells uniquely vulnerable to either drug treatment or gene silencing. Outcomes from this work could lead to new therapeutics personalized treatment for kidney cancer.

DAY 2 – Friday, November 14, 2014 – continued

0930 - 1000
Mezzanine

NUTRITION BREAK, POSTER VIEWING AND JUDGING

1000 - 1130
Shediac B/C

CONCURRENT SESSION – WORKSHOP #3:
NEW BRUNSWICK RESEARCHERS PRESENTATIONS

Chair/Moderator: Mr. Barry Strack, Research Services Manager, Saint John Regional Hospital

Speakers:

Getting to the Heart of Nanoparticle Toxicity Using Fish as a Model System

Dr. Tyson MacCormack
Ph.D., Asst. Prof., Biochem., Mount Allison University

Mount Allison UNIVERSITY

Abstract

Engineered nanomaterials straddle the boundary between the atomic and molecular scale and because of this, they exhibit unique physical, chemical, and electronic properties. Nanoparticles are now found in thousands of consumer products and there is a growing need to characterize their potential health risks. We are addressing this challenge at multiple scales, from isolated proteins and cells to whole animals, and exploiting the tunable nature of nanomaterials to identify how specific properties (e.g. size, shape, charge) influence bioactivity. Using fish as a model system, we have focussed on characterizing the mechanisms by which nanomaterials impact cardiorespiratory physiology and the regulation of heart function in vivo. Identifying the physicochemical properties that contribute to nanoparticle bioactivity will facilitate the design of safe nano-enabled products and provide regulators with the necessary data to make informed decisions on novel materials. The end goal of this research is to ensure the responsible development of nanotechnology applications aimed at addressing critical issues in human and environmental health.

Living with the Cancer Encore: The Experience of People who have had Multiple Cancer Diagnoses

Dr. Krista Wilkins
RN, Ph.D., Asst. Prof., Nursing, UNB

UNB

Abstract

Approximately one in two Canadians will develop some form of cancer, and some will live long enough to be diagnosed with multiple cancers. There is some indication that multiple cancer diagnoses negatively impact a person's quality of life. Studies do not fully capture the complexity of this experience. This presentation will report on the preliminary efforts to capture the shared meanings and common features of what it is like to have multiple cancer diagnoses.



Development of diagnostic tools and novel therapeutic approaches to overcome drug resistance in brain tumours

Dr. Pier Morin
Ph.D., MBA, Asst Prof., Dept of Chem. & Biochem., Université de Moncton,
Adjunct Prof., Dept of Biochem., U de Sherbrooke

UNIVERSITÉ DE MONCTON
EDMUNDSTON MONCTON SHIPPAGAN

Abstract

Malignant gliomas are the most common and deadly brain tumors. Last year, more than 2,600 cases of brain tumors were reported in Canada and the mean survival rate for a patient diagnosed with a glioblastoma multiforme (GBM), the most aggressive glioma, remained slightly over one year. Current standard of care consists of treatment with the alkylating agent temozolomide concurrently or following radiotherapy even though the therapeutic benefits are only marginal. Molecular mechanisms that can contribute to temozolomide resistance in GBMs are starting to emerge. Improving our knowledge of the metabolic cascades associated with inherent and acquired temozolomide resistance in GBMs is, hence, of uttermost importance. Our program utilizes a combination of expertise to not only identify the metabolic cascades involved in temozolomide resistance in GBMs, but to identify key metabolic nodes, such as the repair enzyme MGMT, that could be targeted as part of novel therapeutic strategies for GBM patients not responding to temozolomide. This presentation will tackle these research topics.

DAY 2 – Friday, November 14, 2014 – continued

Hyperleptinemia and decreased male gonadal function

Dr. Luc Martin
Ph.D., Prof. Dept of Biology, Faculty of Science,
Université de Moncton

Abstract

Obesity contributes to reduced fertility in males, as well as increased morbidity for diseases related to a decline in testosterone production with aging. The adipose tissue is an important endocrine organ producing numerous hormones, including leptin, known to inhibit testosterone production during obesity. Interestingly, low testosterone contributes to the accumulation of visceral fat in obese men, thus creating a cycle aggravating the condition of obesity. In this project, we address the mechanisms of action of leptin at the testicular level using cell culture and mice exposed to a high-fat diet. The influences of leptin on steroidogenic gene promoters' activities will also be discussed.



Exploring Metabolic Networks in Health and Disease

Dr. Thomas Pulinilkunnil
Ph.D., Asst. Prof., Dept. Biochem. & Mol. Biology, Dalhousie University;
Adj. Prof., UNBSJ; Research Scientist, DMNB

Abstract

The heart acquires energy via oxidation of various substrates like fatty acid (FA), glucose, triacylglycerol (TAG), lactate, amino acids and ketone bodies. The flexibility in substrate selection is essential for the heart to maintain energy production and contractile function. In a healthy heart glucose accounts for approximately 30%, whereas FA, the preferred substrate, accounts for approximately 65% of the ATP generated. However during obesity and diabetes related heart disease and failure, a maladaptive shift in cardiac metabolism compromises heart function. Studies from our laboratory are aimed at elucidating molecular interplay between glucose, FA, TAG and amino acid metabolism and how these cellular metabolic processes dictates myocardial function and whole body physiology in health and disease. Overall, our studies will allow us to identify molecular targets for therapeutic intervention that will help treat patients at risk for heart failure.

1000 - 1130
Ballroom A/B

CONCURRENT SESSION – WORKSHOP #4:
BIOSCIENCES AND HEALTH: FROM RAW MATERIALS (PLANT, MARINE COPRODUCTS) TO HUMAN CLINICAL TRIALS

Chair/Moderator: **Dr. Jacques Gagnon**, Ph.D., Sci. Dir., Fishery and Marine Products, Coastal Zone Res. Inst. (CZRI); Adj. Prof., Université de Moncton

Speakers:

Natural products from the medicinal plant *Juniperus communis* selectively induce apoptosis in cancer cells

Dr. Chris Gray
Asst-Professor, Natural Products Research Group,
Depts. Chemistry & Biology, UNBSJ

Abstract

Natural products continue to play a pivotal role in the discovery and development of cancer therapeutics. Our investigations of plants commonly used by the indigenous peoples of North America as therapeutics have indicated that these plants could be an important source of natural products with anti-cancer properties. This presentation will illustrate the potential of medicinal plants using our recent work on *Juniperus communis* (common juniper) as an example. Through bioassay-guided fractionation of a crude *J. communis* extract, we identified the diterpene isocupressic acid and the aryltetralin lignan deoxypodophyllotoxin (DPT) as potent inducers of caspase-dependent programmed cell death (apoptosis) in malignant MB231 breast cancer cells. Our results also revealed that DPT inhibits cell survival pathways mediated by the MAPK/ERK and NF-*k*B signaling pathways within hours of treatment. Once again, our work highlights the potential that an ethnopharmacological approach to drug discovery can bring to the development of new therapeutics.

DAY 2 – Friday, November 14, 2014 – continued

Natural health products (NHP) quality analysis and standardization – Overview of new approaches and technologies and applications in shrimp oil analysis

Dr. Junzeng Zhang
Research Officer, National Research Council,
Institute for Nutrisciences and Health

NRC·CNRC

Abstract

The Canadian Natural Health Product (NHP) is internationally recognized for its quality and safety and as such quality remains one of the foremost important issues for the industry. Due to the complexity nature of NHPs, quality may vary considerably and industry accepted standards, and industry accepted QC/QA methods require constant improvement and upgrading to maintain Canada's reputation for quality. The Canadian NHP industry is also dealing with product expansion where an increasing number of imported raw materials or functional ingredients are being added to new NHP products thus increases the need for standards and methods. Therefore, new approaches and more integrated technology platforms are becoming more important for assessing NHP quality, including botanical identity, origin, integrity, that will help to counteract challenges with inferior ingredients and/or substitution or adulteration. As an overview of recent advancement in NHP quality analysis, the presentation will highlight some of the new approaches and technologies in literature, including array-based techniques and direct analysis in real time TOF-MS for identification of raw materials, chromatographic and NMR fingerprinting in coupling with chemometrics, quantitative NMR, and bioresponse fingerprinting in product quality control. Applications of some of these approaches in analysis of shrimp oil will also be presented. In addition, NRC will detail its capacity and expertise that enable customized solutions for quality and standardization that will help the Canadian NHP industry remain synonymous with safety and quality.



Shrimp oil improves glucose metabolism and control in diet-induced insulin-resistant rats

Dr. Yanwen Wang
Research Officer, National Research Council,
Institute for Nutrisciences and Health

NRC·CNRC

Abstract

Shrimp oil contains high quality of fatty acids and antioxidants. Our recent study in diet-induced obese and insulin-resistant rats demonstrated that dietary supplementation of shrimp oil at a dose of 5.6% significantly lowered fasting and semi-fasting blood glucose levels. Rats treated with shrimp oil also showed significant improvements of oral glucose tolerance and insulin response. Shrimp oil did not affect the body weight or food intake. The results demonstrate that shrimp oil is beneficial to glucose metabolism and has potential to be used to prevent or help treat insulin resistance or diabetes.

New Developments of Anti-inflammatory Drugs in the Treatment of depression and neurodegeneration

Dr. Cai Song
Adjunct Professor, Psychology Department, Dalhousie University, Halifax,
Director and Professor, Research Institute for Marine Drug and Nutrition,
Guangdong Ocean University, Zhanjiang, China; Professor, Graduate Institute
of Neural and Cognitive Science, China Medical University, Taichung, Taiwan

DALHOUSIE UNIVERSITY
Inspiring Minds

Abstract

In clinical and experimental studies, eicosapentaenoic acid (EPA) from fish oil has been reported to significantly improve depressive symptoms and memory impairment, which are associated with the reduction of pro-inflammatory mediators and the enhancement of neurotrophic system. Several extractions from shrimp sludge also reduced inflammation and protected neurons from amyloid-beta-induced apoptosis.

Buglossoides arvensis seed oil: an effective and sustainable plant-derived source of dietary omega-3 fatty acids

Dr. Natalie Lefort
Postdoctoral Fellow, Dépt. chimie et biochimie,
Université de Moncton

UNIVERSITÉ DE MONCTON
EDMUNDSTON MONCTON SHIPPAGAN

DAY 2 – Friday, November 14, 2014 – continued

Abstract Health benefits linked to dietary omega-3 (ω-3) fatty acids (FAs) are increasingly acknowledged. However, sustainable alternatives to marine sources of these FAs are being sought to meet the rising global demand. *Buglossoides arvensis* is a wild plant that has been developed for agricultural production whose seed oil is rich in stearidonic acid (SDA, 18:4 ω-3). We will present the results of a randomized, double-blind, comparator-controlled, phase I clinical trial investigating *Buglossoides arvensis* seed oil. Forty participants were randomly assigned to a 4-week, 10 g per day dietary supplementation regimen with either *Buglossoides arvensis* or flax seed oil. Safety was assessed by measuring blood and urine chemistries, while efficacy was assessed by measuring omega-3 FA content in plasma and circulating blood cells.

1000 - 1130
Shediac A

CONCURRENT SESSION – WORKSHOP #5:
CAREER OPTIONS FOR HEALTH GRADUATES

Chair/Moderator: **Dr. Lise Dubois**, Associate VP, Research and Dean, School of Graduate Studies, Université de Moncton

Speakers:

Private Sector Stream
Dr. Stephen Graham
BSc(Pharm), PhD, Medical Science Liaison, GlaxoSmithKline

Abstract Dr Steve Graham, representing the private sector career stream, has worked in the Pharmaceutical industry as a field medical liaison for the past four years, focusing on facilitating health systems research with the goal of improving health outcomes in the Atlantic Region. He also teaches an online course in pharmaco-epidemiology at the College of Pharmacy, University of Florida and he is an adjunct faculty member in the Faculty of Medicine, Dalhousie University. He has worked with the Nova Scotia Department of Health where he managed the evaluation of pharmaceutical policy and was the subject matter expert for the Provincial Drug Information System project. Steve has worked independently as a health outcomes researcher and a relief pharmacist in Nova Scotia. Previous to his academic endeavours he had a career as an Air Navigator and laterally as a Pharmacist in the Canadian Forces.

Academic Stream
Dr. Gilles A. Robichaud
PhD, Professor, Department of Chemistry and Biochemistry, Université de Moncton

Abstract What to do with all that education? In our day, students are at the crossroads of career opportunity in a variety of settings. How does one chose between academia, government or industry. This presentation will bring insight to questions such as: how do I get in; what is the salary; and, are there any jobs? Gilles Robichaud (Université de Moncton) will also attempt to illustrate the academic milieu as a career choice. A breakdown of the assets and tasks at hand for an academic researcher will be presented.

Government Stream
Ms Bronwyn Davies
Executive Director, Community Health Services, NB Department of Health

Abstract What to do with all that education? There are opportunities in a number of distinct settings, broadly categorized as: academia, industry or government. How does one chose between academia, public service in government or industry. This presentation will provide an oversight of the "machinery" of government and answer questions about the diverse opportunities that exist within government. Bronwyn Davies (Department of Health) will broadly discuss the assets and skills required to work within the public sector.

DAY 2 – Friday, November 14, 2014 – continued

1130 - 1300
Ballroom C

LUNCH AND POSTER VIEWING AND REMOVAL

1300 - 1430
Ballroom A/B

CONCURRENT SESSION – WORKSHOP #6:
NEW BRUNSWICK RESEARCHERS PRESENTATIONS

Chair/Moderator: Dr. Dominique Richard, Manager, Research Services, The Moncton Hospital

Speakers:

Associations between relationship status, employment quality, and mental health during the transition to work: Implications for university-based health and counselling services

Dr. José Domene
Ph.D., L.Psych., Prof. and Canada Research Chair,
Faculty of Education, UNB

Abstract

Grounded in Lazarus and Folkman's transactional model of stress and coping, this study involved examining the associations among self-reported depressive symptoms, two aspects of quality of employment, and romantic relationship status, for youth transitioning from school into the workforce. Cross-sectional data were drawn from the Canadian National Longitudinal Survey of Children and Youth, and hierarchical multiple regression analyses were conducted to examine the associations among quality of employment, romantic relationships, and depressive symptoms. Satisfaction with employment emerged as a significant correlate of self-reported depressive symptoms for both males and females, while fit with aspired work was not associated with depressive symptoms in any of the models. After considering the role of quality of employment, being in a romantic relationship did not appear to be a correlate of depressive symptoms.

Using a simple Bayesian framework to improve the control of medical devices, such as prostheses

Dr. Jon Sensinger
Ph.D., Ass. Dir., Institute of Biomedical Engineering (IBME);
Ass. Prof., Dept of Electrical and Computer Engineering, UNB

Abstract

Patients are increasingly improving their quality of life by interacting directly with medical device, either as a rehabilitation aide (such as gait training following a stroke) or as a life-long tool (such as a prosthesis or exoskeleton). Control of these devices is crucial to their performance, and control of devices that interact with humans is a challenging area of research. We have seen promising results in the related field of human-machine interfaces, such as aircraft that can be flown by a pilot even though they're unstable. But many human biosignals offer unique features that make conventional control theories unsuitable for understanding or improving control interfaces for bio-controlled human-machine interfaces. This talk will review the recently developed field of computational motor control, which is able to incorporate the unique characteristics of bio-control signals and accurately predict the way people behave interacting with existing devices. It will go on to show how this framework can be used to accelerate the rate of discovery in higher-performance, more reliable control techniques. The talk will use prostheses as an example, but is relevant to the broader field of bio-controlled human-machine interfaces.

Inside & Out – Translating Research – Innovations to Improved Cardiovascular Outcomes

Dr. Keith Brunt
Ph.D., Asst. Prof., Pharmacology, Dalhousie; Adj. Prof., UNBSJ;
Research Scientist, Dir. Comm. Engagement & Innovation Dev., DMNB

Abstract

The concept of transformative innovation in medicine, which is required to deliver health care in the modern age, will be introduced. Concepts of self-managed care using digital technology and the convergence of scientific fields in nanotechnology to create theranostics – agents that detect, target, and deliver therapy using disease specific mechanisms – will be discussed.

DAY 2 – Friday, November 14, 2014 – continued

Masculinities, Lifetime Violence and Health

Dr. Kelly Scott-Storey
PhD. Faculty of Nursing, UNB

Abstract

Violence is a public health issue. Major causes of death and disability in men (accidents, heart disease, suicide, homicide) can be linked to violence through injury, stress effects, and health risk behaviours; however, violence has not been a health priority despite its prevalence in the lives of men. Studying the effects of gender and cumulative *lifetime* violence on men's health is a promising line of inquiry for gaining new understandings of illness, disability, and death among men. This presentation will focus on the development of a program of research exploring gender, lifetime violence and health.

1300 - 1430
Shediac A

CONCURRENT SESSION – WORKSHOP #7:
MEDIA RELATIONS – VALUE AND PROMOTION OF THE HEALTH RESEARCH ENTERPRISE

Chair/Moderator: Ms. Sophie Thériault, Director, Business Development and Communications, ACRI

Speaker:

Telling your Stories – Why it Matters and How to do it

Mr. Duncan Matheson
President, BissettMatheson Communications

Abstract

The NBHRF is involved in some interesting and important research, but often this work is going on under the radar with few people outside of those directly involved aware of it. This is unfortunate for a number of reasons. This session will explore why it matters, and what you can do about it. This session will focus on how to see the potential story behind your work, why it is in your best interests to tell that story, and tips on how to effectively do it.

1300 - 1430
Shediac B/C

CONCURRENT SESSION – WORKSHOP #8:
ALL SPOR UPDATES

Chair/Moderator: Ms Nancy Roberts, Executive Director,
Health Intelligence and Planning (Branch), GNB-DOH

Speakers:

Maritime SPOR Support Unit (MSSU)

Dr. Mathieu Bélanger
(Representing Dr. Ted McDonald, NB Director, MSSU)
Director of Research, Centre de formation médicale
du Nouveau-Brunswick (CFMNB)

Abstract

With the signing of the funding agreement between CIHR and Capital District Health Authority in June 2013, the Maritime SPOR SUPPORT Unit commenced formal operations. The purpose of this presentation is to provide an update on important developments with the MSSU since then, including organizational structure, milestones, staffing, patient engagement, data development and how the MSSU can and will support patient-oriented health research in the Maritimes. The presentation will also describe progress on the first MSSU demonstration project on cardiac and orthopedic surgical outcomes in among patients resident in NB, NS and PEI.

DAY 2 – Friday, November 14, 2014 – continued

SPOR Network in Primary and Integrated Health Care Innovations

Dr. Baukje Miedema
B.A., M.A., Ph.D., Asst. Prof. & Research Director (Fredericton),
Family Med. Teaching Unit, Dalhousie University

DALHOUSIE UNIVERSITY *Inspiring Minds*

Abstract

A team in New Brunswick has been awarded a SPOR Network development grant to create a *SPOR Network in Primary and Integrated Health Care Innovations*. The Network team is a broad based group of New Brunswick primary and an integrated health care stakeholders that is in the process of preparing a Network of Networks application for April 2015. The Network development grant is supported by the NBHRF.

Transformational Research in Adolescent Mental Health (TRAM)

Mr. Christian Whalen
B.A., Bach. Laws (LLB), Senior Legal Council,
Office of the Child and Youth Advocate, GNB

Child & Youth Advocate Défenseur des enfants et de la jeunesse

Abstract

SPOR TRAM is a $25 million five year program for Transformative Research in Adolescent Mental Health in Canada. Co-funded by CIHR and the Graham Boeckh Foundation in Montreal, TRAM aims to establish a national network of knowledge transfer to improve mental health service delivery for 11 to 25 year olds across Canada. ACCESS is the national network of family, youth, policy, research, clinical and service delivery stakeholders that has been established to lead the five year program of transformation. Within ACCESS, TRAM-NB is positioned as a special demonstration project where improved access to mental health services will be achieved on a provincial scale within five years. This presentation will focus on the New Brunswick partners in the TRAM-NB process and the plans underway provincially to support this transformation in service delivery. Elements of youth empowerment, peer mentorship and community based supports of the proposed transformation will be touched upon, as will the project's links to the provincial health mental action plan, integrated service delivery and the Youth Intervention and Diversion Program in youth corrections. The project's research design and its premises drawn from child rights discourse and social determinants of health measurement will also be presented.

Canadian Consortium in Neurodegeneration and Aging (CCNA)

Dr. Sarah Pakzad
Ph.D., Prof. in Neuropsychology,
Dept. of Psychology, Université de Moncton

UNIVERSITÉ DE MONCTON
EDMUNDSTON MONCTON SHIPPAGAN

Abstract

The Canadian Consortium on Neurodegeneration in Aging (CCNA) project includes research teams from Ontario, Québec and New-Brunswick and focuses on the evaluation of the collaborative models in primary care settings for the elderly patients with dementia. The overall objective of our research program is to understand, refine, improve and facilitate dissemination and scale up successful and sustainable collaborative care models (collCMs) across New-Brunswick. Funding for this project has been secured through CIHR and NBHRF. The project was officially launched in September 2014, the participating Family Health Teams have been identified and implementation of the research protocol is ongoing.

eHealth Innovations Partnership Program (eHIPP)

Dr. Michel Johnson
Ph.D., Prof., School of Kinesiology and Recreation,
Université de Moncton

UNIVERSITÉ DE MONCTON
EDMUNDSTON MONCTON SHIPPAGAN

DAY 2 – Friday, November 14, 2014 – continued

Abstract

This workshop will give a brief overview of the CIHRs new eHealth Innovation Initiative Partnership Program (eHIIPP). This initiative seeks to identify person-oriented eHealth solutions that will improve health outcomes, patient experience, and lower the cost of care along the health care continuum in two priority areas: early identification of and interventions for youth with mental health conditions; and supporting seniors with complex care needs in their homes. It seeks to create collaborative synergies between academics, communities, and industry in order to integrate eHealth innovations into real world service delivery.

1430 - 1530
Ballroom A/B

STUDENT PRIZES – PRESENTATIONS FROM POSTER COMPETITION WINNERS:

Undergraduates and Medical Students – 3 Prizes
Master's Students – 3 Prizes
PhD Students and Past Doctoral Fellows – 3 Prizes
Health Professionals – 2 Prizes

Chair/Moderator:

Dr. Stephen Lewis
President of the Local Organizing Committee of the 2014 Conference, Asst-Director. ACRI, Adjunct-Professor, Université de Moncton

INSTITUT ATLANTIQUE DE RECHERCHE SUR LE CANCER
ATLANTIC CANCER RESEARCH INSTITUTE

1530 - 1545
Ballroom A/B

CLOSING REMARKS NBHRF CHAIRPERSON, AND FAMILY PHOTO OF THE NEW BRUNSWICK COMMUNITY OF HEALTH RESEARCH